| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
|
Purity: ≥98%
Dapoxetine HCl (formerly known as LY210448; LY-210448; trade name Priligy), an antidepressant, is a novel, potent, short-acting and selective serotonin reuptake inhibitor (SSRI) that has alto been used for the treatment of premature ejaculation. It is a novel, short-acting selective serotonin reuptake inhibitor that is marketed to treat men's premature ejaculation. Granisetron inhibits feline isolated ventricular myocytes' delayed rectifier current (IK) at a 4.3 mM KD. Granisetron exhibits an inherent voltage dependence when the depolarization increases the block.
| Targets |
5-HT
|
|
|---|---|---|
| ln Vitro |
|
|
| ln Vivo |
Dapoxetine hydrochloride (oral gavage; 1-10 mg/kg; once daily) significantly reduces the weight gain and relative weight gain of the prostate caused by testosterone and attenuates the prostatic hyperplasia caused by testosterone in rats[2].
|
|
| Animal Protocol |
Adult male Wistar rats
1 mg/kg, 5 mg/kg, 10 mg/kg Oral gavage; 1-10 mg/kg; once daily |
|
| References |
|
| Molecular Formula |
C21H24CLNO
|
|
|---|---|---|
| Molecular Weight |
341.87
|
|
| Exact Mass |
341.15
|
|
| Elemental Analysis |
C, 73.78; H, 7.08; Cl, 10.37; N, 4.10; O, 4.68
|
|
| CAS # |
129938-20-1
|
|
| Related CAS # |
Dapoxetine-d7 hydrochloride; Dapoxetine; 119356-77-3; (rac)-Dapoxetine-d6 hydrochloride
|
|
| Appearance |
Solid powder
|
|
| SMILES |
CN(C)[C@@H](CCOC1=CC=CC2=CC=CC=C21)C3=CC=CC=C3.Cl
|
|
| InChi Key |
IHWDIQRWYNMKFM-BDQAORGHSA-N
|
|
| InChi Code |
InChI=1S/C21H23NO.ClH/c1-22(2)20(18-10-4-3-5-11-18)15-16-23-21-14-8-12-17-9-6-7-13-19(17)21;/h3-14,20H,15-16H2,1-2H3;1H/t20-;/m0./s1
|
|
| Chemical Name |
(1S)-N,N-dimethyl-3-naphthalen-1-yloxy-1-phenylpropan-1-amine;hydrochloride
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9251 mL | 14.6254 mL | 29.2509 mL | |
| 5 mM | 0.5850 mL | 2.9251 mL | 5.8502 mL | |
| 10 mM | 0.2925 mL | 1.4625 mL | 2.9251 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT00211094 | Completed | Drug: Dapoxetine | Ejaculation | Alza Corporation, DE, USA | June 2004 | Phase 3 |
| NCT01419470 | Completed | Drug: dapoxetine | Premature Ejaculation | Yuhan Corporation | February 2011 | Phase 1 Phase 2 |
| NCT01366664 | Completed | Drug: Treatment sequence 2 Drug: Treatment sequence 1 |
Ejaculation | Janssen Research & Development, LLC |
April 2011 | Phase 1 |
| NCT01063855 | Completed | Drug: Dapoxetine Drug: Placebo |
Erectile Dysfunction Sexual Dysfunction |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
April 2010 | Phase 3 |
| NCT01230762 | Completed | Drug: dapoxetine | Ejaculation | Alza Corporation, DE, USA | April 2005 | Phase 3 |
|
|---|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
